MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) the (“Company”), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported that the Company was awarded a government grant amounting to a total net amount of up to NIS 3.0 million ($0.9 million USD), from the Office of the Chief Scientist (OCS) at the Ministry of Industry, Trade and Labor of Israel for the six month period through August 2011.